Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a research report report published on Sunday,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on TVRD. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research report on Wednesday, July 8th. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research report on Wednesday, July 8th. HC Wainwright started coverage on shares of Tvardi Therapeutics in a research note on Monday, June 8th. They set a “buy” rating and a $9.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Wednesday, July 8th. Finally, BTIG Research reduced their target price on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Tvardi Therapeutics Stock Down 5.3%

Shares of TVRD stock opened at $1.08 on Friday. Tvardi Therapeutics has a fifty-two week low of $0.93 and a fifty-two week high of $43.65. The stock has a market cap of $14.41 million, a P/E ratio of -0.39 and a beta of 0.38. The business has a fifty day simple moving average of $1.72 and a 200-day simple moving average of $2.61.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, sell-side analysts anticipate that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new position in Tvardi Therapeutics during the second quarter worth about $34,000. Susquehanna International Group LLP purchased a new stake in Tvardi Therapeutics in the 2nd quarter valued at about $63,000. Finally, BlackRock Inc. acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $181,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s approach is designed to address tumor growth, immune suppression and resistance to existing therapies by selectively targeting STAT3, a protein involved in cancer progression.

Tvardi’s lead product candidate is TTI-101, an orally administered small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors.